Polpharma S.A., Zf

Polpharma has been located in Starogard Gdanski, Poland since 1935 and became private company since 2000. We are focused on development and commercialisation of branded generic drugs. Our huge production capacity enables us selling both: finished dosage forms and active pharmaceutical ingredients. The Synthesis Plant consists of: Salicylic Acid and Derivatives, Sulfonamides, Psychotropics and Custom Synthesis Department. Our history is the implication for continuous improvement. Many investments were made to simplify chemical processes, provide fire protection and safe working conditions. We actively develop new active pharmaceutical ingredients and intermediates. The modern technology and top class equipment guarantee compliance with GMP and GLP rules. The quality of our products is built, like elements of a puzzle, into the each stage of production and later confirmed by quality assuran ce, which is independent of the production personnel. We enjoy the reputation of a manufacturer with the trademark well known to its customers for reliability of the services promised. Our short delivery terms and evolved supply chain make us a good contract partner. Having achieved strong position in Europe and North America, we have been proud of our good economic results for a number of years. We are leading pharmaceutical company in Poland getting up to 11% of the market and having about 200 products in portfolio. Our operations are worldwide focusing on the CEE and CIS countries, In order to protect natural environment we constantly monitor the condition of atmosphere. During the last few years we have reduced the emission of gases into the atmosphere by making technological processes more hermetic. We have developed together with the European standards. It is high time to contact us and to let the cooperation begin. Life is much easier when you have a good business par tner.

Please note!
Collaboration of companies with shared values is main goal of this project.
We will read your message and redirect it to a company's employee whom it can be as useful as possible.
Your company has 5 opportunities per year to get acquainted with other companies. If you want to increase this amount, please contact us
Please note, that according to EBA Code of Conduct it is prohibited to perform on the EBA platform any coordinated actions, which may limit the competition between the EBA Members.
Write us in case of additional questions and suggestions.

Spelling error report

The following text will be sent to our editors: